Engflag

Modificial

Quick links to important sections

Modificial

Modificial_EN

Method of action: Anti-Abstinence, Antiemetic

Treatment option: Acute Nausea And Vomiting, Cancer, Burping, Morning Sickness, Chemotherapy

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Modificial

What is Modificial? Definition and Classification

Quick Facts

Property Description
Active Ingredient Ondansetron
Pharmacological Class Selective 5-HT3 Receptor Antagonist
Common Use Control of Nausea and Vomiting (Emesis)
Origin Synthetic Compound
Key Forms Tablet, ODT, Injectable Solution

Modificial is a prescription-only medication classified as a highly selective antiemetic agent, used specifically to counter the symptoms of nausea and vomiting. The drug is a synthetic, single-ingredient compound containing the active substance, Ondansetron (INN). Ondansetron belongs to a specific group known as Serotonin 5-HT3 Receptor Antagonists, which is its primary pharmacological class. This classification defines the fundamental therapeutic identity of Modificial, indicating it is an agent that manages sickness signals originating from particular neurotransmitter pathways. This mechanism is clinically recognized for providing effective antiemetic relief, particularly in situations where sickness is highly anticipated or recurrent.

Composition and Available Forms

The composition of Modificial is built around its active substance, Ondansetron, and is formulated into preparations suitable for both oral and parenteral administration. The core active component is often supplied as Ondansetron hydrochloride dihydrate. The available forms provide flexibility in delivery; these include standard film-coated tablets, specialized Orally Disintegrating Tablets (ODT) that dissolve rapidly on the tongue, and an oral solution for patients with difficulty swallowing, alongside an injectable solution for intravenous administration. This variety ensures that the medication can be used effectively through either the Oral or Parenteral route, which is a key feature that accommodates patients experiencing acute or persistent vomiting.

General Purpose and Action Principle

The general purpose of Modificial is to control or prevent feelings of nausea and the physical reflex of vomiting (emesis). It achieves this by focusing on the underlying signaling mechanism. The core action principle involves blocking the serotonin signal at the 5-HT3 receptors found in the gut and the brain's vomiting center (Chemoreceptor Trigger Zone). By interrupting this specific chemical communication pathway, Modificial prevents the nervous system from initiating the powerful emetic response. Ondansetron is classified as an essential medicine, recognizing its utility in prophylaxis against emesis associated with specific medical treatments. This confirms the drug’s significant role in providing effective relief from severe sickness signals.

Regulatory References

  1. Serotonin 5-HT3 Receptor Antagonists
  2. WHO Model List of Essential Medicines

What side effects are possible with Modificial?

Possible Side Effects and Safety Information

The safety profile of Modificial (Ondansetron) is organized by frequency and the body system affected, as documented in official government regulatory documents. The most frequently reported adverse event is headache, which is classified as very common in regulatory prescribing information.

Frequency and System-Organ Classification

Frequency Category Representative Reactions System-Organ Class
Very Common Headache Nervous System Disorders
Common Constipation, Diarrhea, Sensation of warmth or flushing Gastrointestinal, Vascular
Uncommon Seizures, Movement disorders, Arrhythmias, Hypotension Nervous System, Cardiac, Vascular
Rare QTc prolongation, Severe Hypersensitivity Reactions, Transient visual disturbances Cardiac, Immune System, Eye
Not Known Myocardial ischemia, Serotonin Syndrome Cardiac, Central Nervous System

Serious Adverse Reactions and Safety Constraints

Regulatory warnings highlight the potential for QTc interval prolongation and the serious risk of a specific abnormal heart rhythm called Torsade de Pointes. Consequently, Modificial is contraindicated in patients with a history of congenital long QT syndrome. Use with the agent apomorphine is also formally contraindicated. Post-marketing reports have identified cases of Serotonin Syndrome (primarily when used with other serotonergic agents) and Myocardial Ischemia.

Specific safety considerations exist for special populations. In patients with severe hepatic impairment, regulatory guidelines limit the total daily dose due to reduced drug clearance. Furthermore, the antiemetic effect may mask signs of a progressive bowel obstruction, such as an ileus or gastric distension, which is noted as a regulatory precaution.

Overdose and Emergency Response

Overdose with Modificial (Ondansetron) is officially documented by regulatory authorities to present with several clinical manifestations. These can include transient blindness, which lasts for a few minutes, severe constipation, hypotension (low blood pressure), and faintness, as well as a vasovagal episode that may involve a transient second-degree heart block.

The most serious outcomes are centered on the cardiovascular system. Overexposure can lead to dose-dependent QT interval prolongation, which carries the risk of a potentially fatal abnormal heart rhythm known as Torsade de Pointes. Neurological compromise is also documented, most notably the emergence of Serotonin Syndrome, which has been reported in both adults and in young children following ingestions exceeding estimated doses. Symptoms of Serotonin Syndrome include agitation, tachycardia, hyperreflexia, and seizure.

Because no specific antidote is known for Modificial overdose, management requires appropriate supportive therapy. Regulators mandate ECG monitoring (cardiac monitoring) and the correction of underlying electrolyte abnormalities to mitigate the risk of severe cardiac events. Immediate medical attention must be sought for any suspected overdose. Emergency services should be contacted if severe symptoms such as collapse, trouble breathing, or seizure occur.

Therapeutic Uses of Modificial

What Modificial treats: Main Uses and Benefits

Modificial (Ondansetron) is a medication generally used to help with symptomatic support by managing the distressing manifestations of nausea, vomiting, and retching. It is generally applied in clinical settings marked by temporary physiological imbalance where symptoms may become more disruptive.

Modificial is used in situations where patients experience nausea and vomiting associated with specific conditions, including cancer chemotherapy, radiation therapy, and surgery.

The agent is commonly used within oncology supportive care to help manage the acute and delayed phases of sickness induced by highly or moderately emetogenic treatments. It is also applied in the surgical setting to help with the management and symptomatic relief of sickness that may follow an operation. Its symptomatic relief supports the ability to maintain oral intake, which may assist with maintaining fluid balance and general well-being during episodes of heightened symptoms.

“This antiemetic support may assist with maintaining a sense of stability and contributes to easing the overall symptom load.”

Quick Fact: Relief for Sickness Symptoms

Use Category Common Clinical Scenario Primary Symptom Relief
Oncology Support Pre- and post-chemotherapy / radiation Managing severe, anticipated nausea
Perioperative Care Post-anesthesia recovery Controlling acute vomiting reflex
Acute Emesis Episodes of intense sickness Easing retching and gagging

Eligibility and Restrictions for Use

Who can and cannot use Modificial? (Ondansetron)

The official eligibility for Modificial is strictly defined by regulatory documents, specifying populations allowed to use the medicine and those who must not.

Contraindicated and Restricted Use

Modificial is contraindicated in patients with a history of hypersensitivity to the drug or any other 5-HT3 receptor antagonist. Absolute prohibition also applies to patients receiving concomitant apomorphine and those with documented congenital Long QT Syndrome.

Use is restricted and requires caution in patients with severe hepatic impairment, where the maximum total daily dose must not exceed 8 mg. Caution is also advised for patients with pre-existing cardiac conditions like bradyarrhythmias or uncorrected electrolyte abnormalities (e.g., hypokalemia).

Age and Reproductive Eligibility

Population Group Eligibility Status
Children (CINV) Eligible from 6 months of age
Infants (PONV) Eligible from 1 month of age
First Trimester Pregnancy Use is generally not recommended
Lactation/Breastfeeding Use is not recommended during treatment

Eligibility for pediatric use is specifically defined by age: 6 months and older for chemotherapy-induced nausea and vomiting (CINV), and 1 month and older for postoperative nausea and vomiting (PONV). Use during the first trimester of pregnancy and during breastfeeding is generally not recommended by regulatory authorities.

What should I know about interactions with other medicines?

Modificial Interactions with other medicines and products

This section outlines interactions with other medicinal products and substances as officially documented in government regulatory labeling for Modificial (Ondansetron).

Prohibited and High-Risk Combinations

Interaction Type Interacting Substance(s) Regulatory Caution
Contraindicated Co-administration Apomorphine Use is strictly prohibited due to the risk of profound hypotension and loss of consciousness.
Additive Pharmacodynamic Risk Serotonergic Drugs (e.g., SSRIs, SNRIs) Co-administration is associated with an increased risk of Serotonin Syndrome.
Additive Cardiac Risk Drugs that Prolong the QT Interval Caution is advised due to the potential for an increased risk of Torsade de Pointes and severe rhythm disturbances.

Interactions Affecting Drug Exposure

Modificial is metabolized by hepatic cytochrome P-450 enzymes (CYP3A4, CYP2D6, CYP1A2). Certain medicines that induce these enzymes may alter Modificial's concentration.

  • Decreased Plasma Concentrations: Potent CYP3A4 inducers, including Phenytoin, Carbamazepine, and Rifampin, are officially documented to increase Modificial's clearance, which results in lower systemic exposure.
  • Reduced Analgesic Effect: The concomitant use of Modificial has been associated with a reduced analgesic effect of Tramadol.

Other Official Interaction Notes

  • Severe Hepatic Impairment: Clearance of Modificial is officially documented as reduced in patients with severe liver impairment, which impacts overall drug handling.
  • Orally Disintegrating Tablet (ODT): The ODT formulation contains Phenylalanine, which must be considered for patients with Phenylketonuria (PKU).

Mechanism of Action

Modificial functions as a non-competitive allosteric inhibitor of the Phosphodiesterase type 4 (PDE4) enzyme, exhibiting selective accumulation within neural and pulmonary tissues. By binding to a regulatory site remote from the active catalytic domain of PDE4, Modificial reduces the enzyme's affinity for its substrate, cyclic adenosine monophosphate (cAMP).

This specific inhibition prevents the hydrolysis of cAMP to inactive 5'-AMP, resulting in an intracellular accumulation of cAMP. The elevated cAMP concentration activates Protein Kinase A (PKA). PKA then initiates a downstream cascade via phosphorylation events that modify the activity of several nuclear transcription factors and cytosolic enzymes.

At a system level, these molecular actions lead to a dose-dependent modulation of neuroinflammatory signaling within the central nervous system and relaxation of smooth muscle in the peripheral vasculature and bronchioles, primarily through PKA-mediated reduction of calcium influx and modifications to the contractile apparatus.

Dosage and Administration Information

How to Use Modificial: Official Administration Guidelines

Modificial (Ondansetron) administration follows standardized protocols and is strictly dependent on the clinical setting and the patient's condition. The usage focuses entirely on prophylactic administration, meaning the medicine must be given prior to the anticipated event (e.g., chemotherapy, radiation, or anesthesia).

Administration Routes and Forms

Modificial is administered via multiple routes to accommodate different patient needs. The primary routes are Oral (as a film-coated tablet, an Orally Disintegrating Tablet (ODT), or an oral solution) and Parenteral (as an Intravenous (IV) or Intramuscular (IM) injection). The ODT must be handled with dry hands and allowed to dissolve on the tongue without chewing.

Labeled Dosing and Timing

Dosage and frequency are tied directly to the emetic risk of the specific medical treatment. For patients undergoing Highly Emetogenic Chemotherapy, the regimen may be a single 24 mg Oral dose taken 30 minutes before the start of treatment. For Moderately Emetogenic Chemotherapy, the dosing regimen typically begins with an initial oral dose, followed by maintenance doses every 8 to 12 hours for up to five days after treatment completion.

For the prevention of Postoperative Nausea and Vomiting (PONV), a single dose, such as 4 mg IV or 16 mg Oral, is typically administered shortly before or after the induction of anesthesia.

Special Procedural Requirements

Intravenous administration protocols require specific preparation: for larger doses (e.g., over 8 mg), the injectable solution must be diluted in a compatible fluid, such as 0.9% Sodium Chloride or 5% Dextrose, and infused over a period of at least 15 minutes. Additionally, a critical clinical constraint mandates that the total daily dose must not exceed 8 mg for adult patients with severe hepatic impairment (liver dysfunction).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Modificial

Evidence for Key Indications

Clinical research for Modificial (Ondansetron) largely consists of Randomized Controlled Trials (RCTs) and Systematic Reviews that explore how symptoms change during periods of acute sickness across its approved uses. For Chemotherapy-Induced Nausea and Vomiting (CINV), studies tracked Complete Response measurements (absence of emesis and rescue medication) in both acute (24-hour) and delayed (five-day) phases across adult and pediatric patients. For Postoperative Nausea and Vomiting (PONV), research primarily evaluated the Incidence of PONV and the need for rescue antiemetic medication during the immediate 24-hour period after surgery. Studies for sickness associated with Radiation Therapy and Acute Gastroenteritis also monitored emesis outcomes within short, defined intervals, with gastroenteritis research specifically observing the reduction in the need for Intravenous (IV) Rehydration.

Long-Term Study Durations and Evidence Gaps

Research exploring the longer-term measured outcomes of Modificial is limited. Most core clinical trials for its approved indications were designed to track symptom patterns for defined short-term intervals (e.g., 24 hours or 5 days). Long-term effects or measured symptom patterns over months are not fully established. There is limited information for outcomes that extend past the timeframe of the initial acute episodes.

Evidence in Special Populations and Uncertainties

Modificial was evaluated in special populations, including infants as young as one month for postoperative sickness and older children for CINV. Data for certain subgroups defined by comorbidities, however, remain insufficient, and results apply only to the populations studied in the official trials. The overall evidence landscape has areas where research remains limited, including follow-up durations and comparative evidence against some newer antiemetic treatments.

Frequently Asked Questions (FAQ)

Common questions about Modificial (FAQ)

Q: Can I take the Orally Disintegrating Tablet (ODT) with a glass of water to help swallow it?

A: The Orally Disintegrating Tablet (ODT) formulation is specifically designed to dissolve quickly on your tongue using only saliva. Official product information indicates that the ODT is intended to dissolve without the need for additional water. The ODT is formulated to be swallowed with saliva, not water.

Q: What should I do with my unused or expired Modificial?

A: Regulatory information recommends that unused or expired medicine should not be flushed down a toilet or sink. The preferred method for disposal is using an official drug take-back program. If a take-back program is unavailable, official guidelines recommend mixing the medicine with an undesirable substance, like used coffee grounds or dirt, before placing it in the trash.

Q: What if I miss a dose of Modificial?

A: Official drug information suggests that a missed dose may generally be taken as soon as it is remembered. However, if it is close to the time for the next scheduled dose, official guidelines indicate that the missed dose should be skipped entirely. Product labeling advises against taking extra medicine or doubling a dose to make up for a missed one.

Q: How long does it take for Modificial to start working after I take the tablet?

A: Studies and official information indicate that the active substance in Modificial is absorbed rapidly after an oral tablet is taken. The peak concentration of the medicine in the bloodstream (known as Tmax) typically occurs approximately one to two hours after taking the tablet. This is the point where the drug reaches its highest measured level in the body.

Q: Does Modificial affect my ability to drive or operate machinery?

A: Official product information suggests that Modificial is not expected to significantly affect the ability to drive or operate complex machinery. However, caution may be necessary because certain side effects, such as dizziness or blurred vision, have been reported in regulatory documents and could potentially affect performance.

How should Modificial be stored and disposed of?

Official Storage and Disposal Instructions

The storage conditions for Modificial (Ondansetron) are defined by regulatory labeling to maintain product stability and integrity. The medicine must be stored at Controlled Room Temperature, typically 20 C to 25 C.

Condition Requirement
Temperature Protect from freezing and excessive heat.
Container Keep in the original package to protect from light.
Safety Store out of the sight and reach of children.

Orally Disintegrating Tablets (ODT) must be protected from moisture and humidity. Once diluted, the injectable solution has a limited stability period (e.g., 24 to 48 hours). Unused or expired Modificial must be disposed of via an official drug take-back program. If a program is unavailable, the drug should be mixed with an undesirable substance before being discarded in the household trash, as flushing is not recommended.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagEcuador

Equivalent of Modificial found in:

A-Z Index: